UPDATE: Canaccord Genuity Raises PT on Biogen Idec on Tecfidera Price Announcement

In a report published Monday, Canaccord Genuity analyst Ritu Baral reiterated a Buy rating on Biogen Idec (NASDAQ: BIIB ), and raised the price target from $200.00 to $206.00. In the report, Baral noted, “Reiterate BUY, increasing target to $206 on newly announced price of Tecfidera (TEC), BIIB's new blockbuster